How to Make Real-World Performance Data Work for Your Trial

Clinical trial teams have access to more data than ever before. Benchmarking databases are growing, AI models are maturing, and cross-industry insights are increasingly available to sponsors and contract research organizations (CROs). But data alone doesn’t automatically translate into better trials. 

WCG’s 2025 Clinical Research Site Challenges Report found that 35 percent of clinical research sites identified protocol complexity as their number one challenge. Meanwhile, Phase III trials have seen a 42 percent increase in required procedures, according to the Tufts Center for the Study of Drug Development. WCG’s KMR data found that in small-cell lung cancer trials, there has been a 75% increase in visits per subject since 2015. These numbers don’t tell a story of teams lacking data. They tell a story of data that isn’t being applied early enough, or precisely enough, to change outcomes. 

One additional endpoint, one extra visit, one overly conservative exclusion criterion can meaningfully increase participant burden, slow enrollment, and trigger costly amendments. Before finalizing your next protocol, consider how your team can use real-world performance data to answer the right questions. 

Step 1: Start with Reflecting on Your Current Processes 

Firstly, ask your team how design decisions are actually being made.  

• Are exclusion criteria carried forward from earlier phases without re-evaluation?  

• Are visit schedules built around scientific habit rather than participant experience?  

• Are burden estimates based on assumption rather than evidence? 

Protocol design often inherits the conservatism of past programs. Sponsors frequently lack comparative data to justify relaxing criteria, even when those criteria may be unnecessarily restricting eligible participant populations. Leveraging a robust, data-backed feasibility tool will surface these exact kinds of design outliers, show where a protocol stacks up against peer trials in comparable indications, and identify where simplification could expand access without compromising scientific integrity. 

Most protocols will experience three or more amendments, which lengthens timelines and slows the delivery of life-saving therapies to the patients who need them most. By implementing design review earlier in the process, most amendments can be avoided. 

Step 2: Be Curious About Gaps in Your Data and Look to Close Them 

Many sponsors rely on internal trial data alone, which limits visibility into how their protocols compare to the broader landscape. Internal datasets reflect your own programs, not the full range of design choices, performance outcomes, and site behaviors across the industry. 

This is where cross-industry benchmarking becomes a genuine strategic asset. Connecting protocol design decisions with real-world operational outcomes, including enrollment velocity, deviation rates, dropout patterns, and timeline drivers, gives teams the visibility they need to make informed choices. Teams can simulate alternative visit schedules, model the impact of loosening an exclusion criterion, or evaluate whether a subgroup detection target is realistic within a planned timeline. 

The gaps worth closing aren’t always obvious. They may appear in how your team selects countries and sites, relying on prior relationships rather than multidimensional performance data. They may also appear in how burden is estimated, without quantifying visit frequency, assessment duration, or logistics in any structured way. Purpose-built feasibility tools can rank geographies, sites, and principal investigators using historical performance, protocol scoring, competitive intelligence, and demographic enrollment profiles, so placement decisions are grounded in evidence rather than familiarity. 

Staying curious means regularly asking whether your current tools give you the visibility you need, and whether gaps in your data are silently shaping decisions you believe are evidence-based. 

Step 3: Make Data-Driven Optimization the “New Normal” 

The Food and Drug Administration’s (FDA) December 2025 finalized guidance on enhancing participation in clinical trials, “Enhancing Participation in Clinical Trials: Eligibility Criteria, Enrollment Practices, and Trial Designs,” makes it clear that inclusive, representative trial design is now an operational expectation, not an ethical aspiration. Sponsors are called to broaden eligibility, reduce burden, adopt flexible designs, and plan for subgroup insights, all before trials begin. 

Meeting that standard consistently requires making data-driven optimization a standard part of protocol development, not an exception applied when a study is already in trouble.  

Advanced feasibility forecasting tools operationalize the shift to data-driven protocol development across three dimensions: 

• From Intention to Evidence: Quantifying burden, comparing eligibility, and forecasting operational performance outcomes by using rich protocol and performance datasets can turn inclusive design from principle into practice. 

• From Reactive Fixes to Prespecified Adaptability: By correlating protocol elements to real-world outcomes, teams can design adaptive pathways that enable broader participation. 

• From Generic Feasibility to Strategic Placement: Country and site ranking grounded in multidimensional fit, including experience, historical capacity, and protocol demands, ensures access and performance aren’t trade-offs. They become mutually reinforcing. 

Building these capabilities into your standard planning process, rather than treating them as optional enhancements, is what separates teams that manage complexity from teams that prevent it. 

Using Benchmarking Data to Design Trials That Work from the Start 

Real-world performance data has real power. It can surface hidden burden before it drives dropout, identify site selection risks before they delay enrollment, and reveal whether a protocol’s eligibility criteria are unnecessarily narrow. But that power depends entirely on how and when it’s applied. 

The teams getting the most value from benchmarking data aren’t using it to validate decisions already made. They’re using it to challenge assumptions during protocol design, close gaps in their internal visibility, and build the kind of defensible, inclusive trial plans that align with FDA expectations from day one. 

WCG’s ClinSphere Trial IntelX™ draws on more than 80,000 complete protocols and 40,000 benchmarked trials, allowing teams to forecast various outcomes based on real-world data. Leveraging AI-enabled foresight means less reactive problem solving and more proactive planning – saving timelines, reducing burden, and helping bring life-saving therapies to the patients who need them most. If your team is ready to see how Trial IntelX can inform your next protocol design, fill out the form below to learn more and schedule a demo. 

Frequently Asked Questions